Advertisement

Lymphoma

  • Yasemin BolukbasiEmail author
  • Duygu Sezen
  • Yucel Saglam
  • Ugur Selek
Chapter

Abstract

This chapter on lung cancers is aiming to summarize the evidence-based current management for lymphoma, covering Hodgkin’s and Non-Hodgkin’s Lymphoma. We hope to ease the understanding in the appropriate delineation of tumor volumes/fields along with related case presentations covering diagnostic images, contouring, slice by slice final plan examples; accompanied by up-to-date key literature review.

References

  1. 1.
    Ansell SM. Hodgkin lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(4):434–42.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Salati M, et al. Epidemiological overview of Hodgkin lymphoma across the Mediterranean Basin. Mediterr J Hematol Infect Dis. 2014;6(1).CrossRefGoogle Scholar
  3. 3.
    Amitai I, et al. PET-adapted therapy for advanced Hodgkin lymphoma—systematic review. Acta Oncol. 2018:1–8.Google Scholar
  4. 4.
    Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–15.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Ferme C, et al. ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin lymphoma with risk factors: results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d’Etude des Lymphomes de l’Adulte (GELA) H9-U intergroup randomised trial. Eur J Cancer. 2017;81:45–55.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Andre MPE, et al. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2017;35(16):1786–94.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Specht L, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Bartlett NL. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy. In American Society of Clinical Oncology educational book; 2013. p. 374–80.CrossRefGoogle Scholar
  9. 9.
    Hoppe RT, et al. Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(5):608–38.CrossRefGoogle Scholar
  10. 10.
    Hoskin PJ, et al. Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol (R Coll Radiol). 2005;17(1):47–53.CrossRefGoogle Scholar
  11. 11.
    Maraldo MV, et al. Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):144–52.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol. 2004;52(1):19–32.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Levin LI, et al. Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma. Blood. 2012;120(18):3750–5.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–32.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Lee AI, LaCasce AS. Nodular lymphocyte predominant Hodgkin lymphoma. Oncologist. 2009;14(7):739–51.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Goel A, et al. Nodular lymphocyte predominant Hodgkin lymphoma: biology, diagnosis and treatment. Clin Lymphoma Myeloma Leuk. 2014;14(4):261–70.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Blank O, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017;4:CD007110.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Nguyen VT, et al. Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning. Br J Haematol. 2017;179(4):674–6.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339(21):1506–14.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Aleman BM, et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2007;67(1):19–30.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Hutchings M, et al. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol. 2007;78(3):206–12.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Oner AO, et al. Efficacy of (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computerized tomography for bone marrow infiltration assessment in the initial staging of lymphoma. Mol Imaging Radionucl Ther. 2017;26(2):69–75.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Kanoun S, Rossi C, Casasnovas O. [(18)F]FDG-PET/CT in Hodgkin lymphoma: current usefulness and perspectives. Cancers (Basel). 2018;10(5). pii: E145.Google Scholar
  24. 24.
    Karls S, Shah H, Jacene H. PET/CT for lymphoma post-therapy response assessment in other lymphomas, response assessment for autologous stem cell transplant, and lymphoma follow-up. Semin Nucl Med. 2018;48(1):37–49.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Kasamon YL, Wahl RL. FDG PET and risk-adapted therapy in Hodgkin’s and non-Hodgkin’s lymphoma. Curr Opin Oncol. 2008;20(2):206–19.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Buchpiguel CA. Current status of PET/CT in the diagnosis and follow up of lymphomas. Rev Bras Hematol Hemoter. 2011;33(2):140–7.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Specht L, Yahalom J. The concept and evolution of involved site radiation therapy for lymphoma. Int J Clin Oncol. 2015;20(5):849–54.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Engert A, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol. 2007;25(23):3495–502.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Press OW, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol. 2001;19(22):4238–44.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Fermé C, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. New Engl J Med. 2007;357(19):1916–27.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Engert A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2003;21(19):3601–8.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Noordijk EM, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006;24(19):3128–35.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Bonadonna G, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol. 2004;22(14):2835–41.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Eghbali H, Brice P, Creemers GY, Marwijk Kooij M, Carde P, Van’t Veer MB. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin’s lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial. In ASH annual meeting abstracts; 2005. p. 814.Google Scholar
  35. 35.
    Engert A, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. New Engl J Med. 2010;363(7):640–52.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Meyer RM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. New Engl J Med. 2012;366(5):399–408.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Eich HT, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Radford J, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. New Engl J Med. 2015;372(17):1598–607.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Sickinger MT, et al. PET-adapted omission of radiotherapy in early stage Hodgkin lymphoma—a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;101:86–92.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Johnson PW, et al. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010;28(20):3352–9.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Laskar S, et al. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22(1):62–8.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Borchmann P, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage Hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol. 2011;29(32):4234–42.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Engert A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791–9.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Eichenauer DA, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015;33(26):2857–62.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Voong KR, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol. 2014;9:94.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Petersen PM, et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol. 2015;54(1):60–6.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Maraldo MV, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013;24(8):2113–8.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Horwitz SM, et al. NCCN guidelines insights: non-Hodgkin’s lymphomas, version 3. J Natl Compr Cancer Netw. 2016;14(9):1067–79.CrossRefGoogle Scholar
  49. 49.
    Brittinger G. Histopathology and clinical problems in non-Hodgkin lymphomas. Blut. 1981;43(3):139–41.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Gospodarowicz M. Radiotherapy in non-Hodgkin lymphomas. Ann Oncol. 2008;19(Suppl 4):iv47–50.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):97–110.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Fowler N. Indolent and mantle cell NHL: the future is BRIGHT. Blood. 2014;123(19):2905–6.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Vitolo U, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v91–v102.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Wang SS, et al. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014;2014(48):66–75.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Ascari E, Gobbi PG. Prognostic factors in malignant lymphomas (Hodgkin and non-Hodgkin). Acta Haematol. 1987;78(Suppl 1):146–50.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Yahalom J, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92(1):11–31.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Ng AK, et al. Role of radiation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;100(3):652–69.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Illidge T, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94.Google Scholar
  61. 61.
    Federico M, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27(27):4555–62.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Hoster E, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–65.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–67.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Hoskin PJ, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–63.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Tang T, Martin P. When indolent follicular lymphoma is not indolent. Leuk Lymphoma. 2014;55(11):2417–8.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Brem EA, Davids MS. Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma? Leuk Lymphoma. 2014;55(12):2675–7.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Lossos IS, Gascoyne RD. Transformation of follicular lymphoma. Best Pract Res Clin Haematol. 2011;24(2):147–63.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Campbell BA, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–806.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Vargo JA, et al. What is the optimal management of early-stage low-grade follicular lymphoma in the modern era? Cancer. 2015;121(18):3325–34.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Vannata B, Stathis A, Zucca E. Management of the marginal zone lymphomas. Cancer Treat Res. 2015;165:227–49.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Juarez-Salcedo LM, et al. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment. Cancer Control. 2018;25(1):1073274818778256.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Zucca E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101(7):2489–95.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Kempf W, Kerl K, Mitteldorf C. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):24–9.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Davies A. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently? Hematology Am Soc Hematol Educ Program. 2017;2017(1):284–94.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Alizadeh AA, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.CrossRefGoogle Scholar
  76. 76.
    Rosenwald A, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Frick M, Dörken B, Lenz G. The molecular biology of diffuse large B-cell lymphoma. Ther Adv Hematol. 2011;2(6):369–79.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Stephens DM, et al. Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736. J Clin Oncol. 2016;34(25):2997–3004.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Horning SJ, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22(15):3032–8.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Reyes F, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. New Engl J Med. 2005;352(12):1197–205.PubMedCrossRefPubMedCentralGoogle Scholar
  81. 81.
    Phan J, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170–6.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Vargo JA, et al. Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol. 2015;33(32):3710–7.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Odejide OO, et al. Limited stage diffuse large B-cell lymphoma: comparative effectiveness of treatment strategies in a large cohort of elderly patients. Leuk Lymphoma. 2015;56(3):716–24.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Pfreundschuh M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Held G, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115–22.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Dabrowska-Iwanicka A, Walewski JA. Primary mediastinal large B-cell lymphoma. Curr Hematol Malig Rep. 2014;9(3):273–83.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Tai WM, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients. Leuk Lymphoma. 2011;52(4):604–12.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    Fuertes S, et al. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2013;40(4):496–504.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Sehn LH, Klasa R, Shenkier T, et al. Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Oral presentation. Hematol Oncol. 2013;31(Suppl. I):96–150. [Abstract]. End-of-therapy PET scan to guide consolidation radiotherapy in aggressive B-cell lymphoma.Google Scholar
  90. 90.
    Pfreundschuh M, Christofyllakis K, Altmann B, et al. Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL. J Clin Oncol. 2017;35:abstr 7506.CrossRefGoogle Scholar
  91. 91.
    Lowry L, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Aristophanous M, et al. Deep-inspiration breath-hold intensity modulated radiation therapy to the mediastinum for lymphoma patients: setup uncertainties and margins. Int J Radiat Oncol Biol Phys. 2018;100(1):254–62.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Yasemin Bolukbasi
    • 1
    • 2
    Email author
  • Duygu Sezen
    • 3
  • Yucel Saglam
    • 3
  • Ugur Selek
    • 2
    • 4
  1. 1.Department of Radiation Oncology, Faculty of MedicineKoç UniversityIstanbulTurkey
  2. 2.Department of Radiation OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Department of Radiation OncologySchool of Medicine, Koç UniversityIstanbulTurkey
  4. 4.Department of Radiation OncologyKoç UniversityIstanbulTurkey

Personalised recommendations